Inspiratory Muscle Training (IMT) in Adult People With Pompe Disease

NCT ID: NCT05951790

Last Updated: 2023-07-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-03-01

Study Completion Date

2024-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this multicentre, randomized and controlled cross-over trial is to evaluate the efficacy of a programme of Inspiratory Muscle Training in subjects with Late On-set Pompe Disease (LOPD). The main question is to:

* verify changes in Forced Vital Capacity, Postural Drop, Maximal Inspiratory Pressure, Maximal Expiratory Pressure, Peak expiratory cough pressure, Maximal Inspiratory Capacity, six- minute walk test and or 6-minute pegboard ring test.-
* measure changes in some questionnaries investigating dispnoea and quality of life (Short-Form 36, Individualized-Neuromuscular-Quality-of-Life, Maugeri-Respiratory-Failure 28, Borg scale, Dispnoea 12, Mulditimensional Dispnea Profile, modified Medical Research Council, Fatigue Severity Scale, Epsworth Scale, Visual Analogue Scale).

Measurement will take place at baseline and after one, three, four, six and twelve months.

Participants will undergo a specific treatment consisting of aerobic exercise and Inspiratory Muscle Training with Powerbreathe device or Air-Stacking.

Researchers will study if Powerbreathe device is more effective than Air-stacking maneuvres

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is an experimental study (Multicentre, randomized and controlled cross-over trial) with low risk impact. The literature supports us in determining that the risks of respiratory muscle fatigue, which will be carefully evaluated through standardized measures of dyspnea, are nonexistent1Patients will undergo respiratory function tests with evaluation of the following parameters: forced vital capacity (FVC %) sitting on their back with measurement of postural fall ie the percentage difference between FVC in sitting and supine position (%PD), maximum inspiratory pressure (MIP), maximum expiratory pressure (MEP), peak expiratory flow during coughing (PCEF), maximum insufflation capacity (MIC), 6-minute walk test (6MWT) for walking patients and six-minute pegboard and ring test (6PBRT) "Ring testing" for non-dombulants. Also participants will compile some questionnaries investigating dispnea, sleep and quality of life (Short Form-36, Individualized-Neuromuscular-Quality-of-Life, Maugeri-Respiratory-Failure 28, Borg scale, Dispnea-12, Muldimensional Dispnea Profile, modifier Medical Research Council, Fatigue Severity Scale, Epsworth Sleepness Scale and Visual Analogue Scale). The evaluation phase identifies zero time (T0). Subsequently, patients enrolled will be randomized to the first treatment (training of inspiratory muscles) or the second treatment (training of inspiratory muscles + air-stacking). Each training period of the respiratory muscles will last 2 months and will be followed by a wash out period of 1 month before moving on to the next arm treatment. The first month patients will perform only aerobic activity. The total treatment time will be 6 months. walking patients will perform an aerobic activity of their choice, according to individual preferences, involving as many muscles as possible (e.g. walking, pedaling, climbing stairs) for at least 30 minutes 3 v/week of sufficient intensity to determine an increase in heart rate (FC) 60% of the predicted FC max or a perception of effort between 4-6 of the modified Borg scale.

For patients who are not walking, there are activities with arms not supported (initially without load and then with small weights of ½ Kg, 1 Kg, 2 Kg) involving the main muscle groups of the upper limbs performed for at least 30 minutes 3 v/week and of such intensity as to generate a perception of effort between 4-6 of the modified Borg scale. The type of instrument used for the training of inspiratory muscles will be the Powerbreathe KHP2 which is a tool with variable load (Fig 1) and can be set according to the characteristics of individual patients as explained below. Intensity and mode of training of inspiratory muscles (8-10 repetitions for 4 sets/day with breaks of at least 2 minutes between one series and the other for 6 days/week) Initial load 30% MIP (the load must be progressively increased to the maximum tolerated level) Patients will be instructed to perform a complete inhalation and exhalation at each respiratory act (about 70% of their CVF).

The respiratory effort perceived by patients should ideally be between 4-6 of the modified Borg scale. Increase of 2 cmH2O with Borg \< 4 or average inhaled volume \< 70% of CVF. Air "stacking" maneuver in the respiratory shaft through the use of an Ambu balloon: the patient encases and retains a series of volumes of air until reaching his MIC (Maximum Inspiratory Capacity) for 10 maneuvers/ day for 6 days/ week.

Patients will be evaluated at the reference hospital centre and will perform the programme at home. They will be followed by physiotherapists specialized in respiratory physiotherapy and the intervention will be articulated with home visits alternated with reinforcement calls and monitoring in equivalent number in the two treatment groups. Follow-up measures will be performed at 1 month (T1), 3 months (T3), 4 months (T4), 6 months (T6) and 12 months (T12).

Patient diaries and records of functional data and load increases will be evaluated. A subject who performs at least 2/3 sessions per week of aerobic training for at least 5/6 months will be defined as adhering to the treatment; 5/6 sessions per week of training of breathing muscles with at least 3/4 series completed, 5/6 sessions per week of air stacking with 8/10 managements carried out.

Also will be measured: Number of phone calls/video calls made by patients in addition to those scheduled; Number of patients in drop out; Number of accesses to the prescribing center for any clinical urgencies; Number of unscheduled visits; Questionnaire of satisfaction to the use of the device. Randomization will be carried out through a derived Internet randomization software in order to ensure the concealment of assignments.

Twenty participants will be randomized (1:1) in blocks of 2 to the trial treatment or control arm. The randomization model will be defined by the study statistician. Based on the defined parameters, the module creates an assignment table model, which is used to structure the randomization table. The module also monitors the overall progress of the assignment and the allocation of randomized participants. The doctor, to collect the data, will use as a password protected Microsoft Excel database. This will happen after the pre-test evaluation and before the first treatment session. The randomization field will always be locked and unmodifiable both before and after the randomization of a participant. The randomization documentation will be stored electronically in Excel and will include the participant identifier, the assignment to the treatment or control arm and the date and time of randomization. This electronic register of randomization will be accessible only to the doctor (not blind). Within each study arm, categorical data will be presented as frequencies and percentages; continuous data will be presented as mean, median, standard deviation and range. Primary analysis of the study will be conducted on intention-to-treat (ITT) cases. Non-directional hypotheses (two-tailed tests) will be tested. The measurement of the primary outcome defined by changes in vital capacity, drop posture and maximum inspiratory pressure will be evaluated with alpha=0.05. The results of the secondary outcomes will be evaluated with and without adjustment for multiple comparisons using the Bonferroni test. In addition, the analyses will be conducted on the participants who completed the study. All data analysis will be performed with the statistical software Jamovi version 2.3.3. No intermediate analysis.It is expected from this study that the training of inspiratory muscles can contribute to an improvement in respiratory function and that this results in a better quality of life

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Glycogen Storage Disease Type II Pompe Disease (Late-onset)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Inspiratory Muscle Training (IMT)

Use of Powerbreathe Device associated with aerobic excercise tailored for walking and non-walking subjects

Group Type ACTIVE_COMPARATOR

Inspiratory Muscle Training (IMT)

Intervention Type DEVICE

Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in

Inspiratory Muscle Training (IMT) + Air Stacking

Intervention Type DEVICE

Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in, along with Air Stacking (AS). AS is a lung insufflation method that requires the use of a manual insufflator to provide air volumes higher than inspiratory capacity

Inspiratory Muscle Training (IMT) + Air Stacking

Use of Powerbreathe Device and application of Air-Stacking maneuvres associated with aerobic excercise tailored for walking and non-walking subjects

Group Type EXPERIMENTAL

Inspiratory Muscle Training (IMT)

Intervention Type DEVICE

Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in

Inspiratory Muscle Training (IMT) + Air Stacking

Intervention Type DEVICE

Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in, along with Air Stacking (AS). AS is a lung insufflation method that requires the use of a manual insufflator to provide air volumes higher than inspiratory capacity

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Inspiratory Muscle Training (IMT)

Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in

Intervention Type DEVICE

Inspiratory Muscle Training (IMT) + Air Stacking

Inspiratory muscle training (IMT) involves breathing exercises using a pressure threshold device to strengthen the muscles involved in breathing in, along with Air Stacking (AS). AS is a lung insufflation method that requires the use of a manual insufflator to provide air volumes higher than inspiratory capacity

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Late On-set Pompe Disease diagnosis already in Enzyme Replacement Therapy (ERT) since 12 months
* Forced Vital Capacity \<80% predicted or Forced Vital Capacity \>80% but with Postural Drop \>25-30%

Exclusion Criteria

* Severe Cardiologic or Respiratory comorbidities
* Complete dependence on ventilation
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Associazione Italiana Glicogenosi (AIG)

UNKNOWN

Sponsor Role collaborator

Associazione Riabilitatori Insufficienza Respiratoria (ArIR)

UNKNOWN

Sponsor Role collaborator

U.O.C. AO Ospedali Riuniti Villa Sofia-Cervello, Palermo

UNKNOWN

Sponsor Role collaborator

S.C. di Pneumologia Azienda Sanitaria Universitaria Integrata di Trieste

UNKNOWN

Sponsor Role collaborator

Fondazione Don Carlo Gnocchi Onlus

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Paolo Banfi

Head of the Cardio-Pulmonary Rehabilitation Unit

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Paolo Banfi, MD

Role: PRINCIPAL_INVESTIGATOR

IRCCS Fondazione Don Carlo Gnocchi

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

IRCCS S. Maria Nascente - Fondazione Don Carlo Gnocchi

Milan, , Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Elena Compalati, RT

Role: CONTACT

3209727740 ext. +39

Marta Lazzeri, RT

Role: CONTACT

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Paolo Banfi, MD

Role: primary

+390240308812

References

Explore related publications, articles, or registry entries linked to this study.

Ambrosino N, Confalonieri M, Crescimanno G, Vianello A, Vitacca M. The role of respiratory management of Pompe disease. Respir Med. 2013 Aug;107(8):1124-32. doi: 10.1016/j.rmed.2013.03.004. Epub 2013 Apr 12.

Reference Type RESULT
PMID: 23587901 (View on PubMed)

Iolascon G, Vitacca M, Carraro E, Chisari C, Fiore P, Messina S, Mongini TEG, Sansone VA, Toscano A, Siciliano G. The role of rehabilitation in the management of late-onset Pompe disease: a narrative review of the level of evidence. Acta Myol. 2018 Dec 1;37(4):241-251. eCollection 2018 Dec.

Reference Type RESULT
PMID: 30944902 (View on PubMed)

Pellegrino GM, Corbo M, Di Marco F, Pompilio P, Dellaca R, Banfi P, Pellegrino R, Sferrazza Papa GF. Effects of Air Stacking on Dyspnea and Lung Function in Neuromuscular Diseases. Arch Phys Med Rehabil. 2021 Aug;102(8):1562-1567. doi: 10.1016/j.apmr.2021.01.092. Epub 2021 Mar 9.

Reference Type RESULT
PMID: 33711277 (View on PubMed)

Jevnikar M, Kodric M, Cantarutti F, Cifaldi R, Longo C, Della Porta R, Bembi B, Confalonieri M. Respiratory muscle training with enzyme replacement therapy improves muscle strength in late - onset Pompe disease. Mol Genet Metab Rep. 2015 Oct 29;5:67-71. doi: 10.1016/j.ymgmr.2015.09.007. eCollection 2015 Dec.

Reference Type RESULT
PMID: 28649546 (View on PubMed)

Jones HN, Crisp KD, Robey RR, Case LE, Kravitz RM, Kishnani PS. Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD): Effects of training and detraining. Mol Genet Metab. 2016 Feb;117(2):120-8. doi: 10.1016/j.ymgme.2015.09.003. Epub 2015 Sep 8.

Reference Type RESULT
PMID: 26381077 (View on PubMed)

Aslan GK, Huseyinsinoglu BE, Oflazer P, Gurses N, Kiyan E. Inspiratory Muscle Training in Late-Onset Pompe Disease: The Effects on Pulmonary Function Tests, Quality of Life, and Sleep Quality. Lung. 2016 Aug;194(4):555-61. doi: 10.1007/s00408-016-9881-4. Epub 2016 Apr 22.

Reference Type RESULT
PMID: 27106274 (View on PubMed)

Wenninger S, Greckl E, Babacic H, Stahl K, Schoser B. Safety and efficacy of short- and long-term inspiratory muscle training in late-onset Pompe disease (LOPD): a pilot study. J Neurol. 2019 Jan;266(1):133-147. doi: 10.1007/s00415-018-9112-4. Epub 2018 Nov 14.

Reference Type RESULT
PMID: 30430231 (View on PubMed)

Jones HN, Kuchibhatla M, Crisp KD, Hobson Webb LD, Case L, Batten MT, Marcus JA, Kravitz RM, Kishnani PS. Respiratory muscle training (RMT) in late-onset Pompe disease (LOPD): A protocol for a sham-controlled clinical trial. Mol Genet Metab. 2019 Aug;127(4):346-354. doi: 10.1016/j.ymgme.2019.05.001. Epub 2019 May 8.

Reference Type RESULT
PMID: 31303277 (View on PubMed)

Jones HN, Kuchibhatla M, Crisp KD, Hobson-Webb LD, Case L, Batten MT, Marcus JA, Kravitz RM, Kishnani PS. Respiratory muscle training in late-onset Pompe disease: Results of a sham-controlled clinical trial. Neuromuscul Disord. 2020 Nov;30(11):904-914. doi: 10.1016/j.nmd.2020.09.023. Epub 2020 Sep 28.

Reference Type RESULT
PMID: 33127291 (View on PubMed)

Human A, Morrow BM. Inspiratory muscle training in children and adolescents living with neuromuscular diseases: A pre-experimental study. S Afr J Physiother. 2021 Aug 31;77(1):1577. doi: 10.4102/sajp.v77i1.1577. eCollection 2021.

Reference Type RESULT
PMID: 34522820 (View on PubMed)

Pick HJ, Faghy MA, Creswell G, Ashton D, Bolton CE, McKeever T, Lim WS, Bewick T. The feasibility and tolerability of using inspiratory muscle training with adults discharged from the hospital with community-acquired pneumonia. Adv Respir Med. 2021;89(2):216-220. doi: 10.5603/ARM.a2021.0002. Epub 2021 Apr 21.

Reference Type RESULT
PMID: 33881155 (View on PubMed)

McCool FD, Tzelepis GE. Inspiratory muscle training in the patient with neuromuscular disease. Phys Ther. 1995 Nov;75(11):1006-14. doi: 10.1093/ptj/75.11.1006.

Reference Type RESULT
PMID: 7480122 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

FDG_LOPD01

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.